{"id":128,"date":"2008-10-30T20:22:19","date_gmt":"2008-10-30T19:22:19","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=128"},"modified":"2013-08-23T13:36:39","modified_gmt":"2013-08-23T13:36:39","slug":"brazil-rejects-gilead-patent-on-tenofovir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/128","title":{"rendered":"Brazil rejects Gilead patent on tenofovir"},"content":{"rendered":"<p><strong>The Brazilian Patent Office has rejected a patent application filed by Gilead Sciences for tenofovir (Viread), currently one of the key antiretrovirals needed in resource-limited countries. The application was opposed by a coalition of Brazilian NGOs and a government pharmaceutical laboratory.<\/strong><\/p>\n<p>A statement from Gilead stated that previous patent rejections, including in the US had been overturned on appeal and that the company &#8220;remain confident in the strength of our intellectual property for tenofovir and plan to vigorously defend the patent and the scientific innovation on which it is based&#8221;.<\/p>\n<p>Several companies in India already make tenofovir (including an WHO-approved version for $158 per year) after Gilead reached agreement with several generic manufacturers not to enforce its patents. Some of the Indian manufacturers and community organisations still object to Gilead&#8217;s patent claim that under the Indian patent system. Gilead&#8217;s tenofovir currently costs $1,387 in Brazil and is used by almost 40,000 patients.<\/p>\n<p>Source: www.pharmalot.com (3 September 2008) <a href=\"http:\/\/www.pharmalot.com\/2008\/09\/brazil-rejects-gilead-patent-on-hiv-drug\/\"><br \/>\nhttp:\/\/www.pharmalot.com\/2008\/09\/brazil-rejects-gilead-patent-on-hiv-dru g<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Brazilian Patent Office has rejected a patent application filed by Gilead Sciences for tenofovir (Viread), currently one of the key antiretrovirals needed in resource-limited countries. The application was opposed by a coalition of Brazilian NGOs and a government pharmaceutical &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-128","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=128"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/128\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}